Development and validation of the Nightingale Symptom Assessment Scale (N-SAS) and predictors of the quality of life of the cancer patients in Turkey

被引:18
作者
Can, Gulbeyaz [1 ]
Aydiner, Adnan [2 ]
机构
[1] Istanbul Univ, Florence Nightingale Sch Nursing, Abide I Hurriyet Cad, TR-34387 Istanbul, Turkey
[2] Istanbul Univ, Inst Oncol, TR-34387 Istanbul, Turkey
关键词
Cancer patient; Quality of life; Chemotherapy; Biotherapy; Side effects; Cancer; Scale; Instrument; BREAST-CANCER; SOCIAL SUPPORT; TURKISH PATIENTS; ONCOLOGY; CHEMOTHERAPY; QLQ-C30; TRIAL;
D O I
10.1016/j.ejon.2009.10.010
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Treatment-related side effects have an adverse impact on the health-related quality of life (HRQoL) of cancer patients undergoing chemotherapy. This study is a description of the validity and responsiveness demonstrated by a new cancer and cancer treatment-specific symptom scale - the Nightingale Symptom Assessment Scale (N-SAS) - which was developed and validated to address the QoL of Turkish cancer patients. Method: The comprehensiveness and clarity of the scale was assessed using 10 patients and pilot testing was carried out with 179 patients. A sample of 374 cancer patients who had received chemotherapy participated in the main study. Descriptive statistics were calculated and comparative tests and factor analysis were performed. Results: The internal reliability of N-SAS was examined and the validity of this scale was determined by correlation with FACT-G. The scale showed high internal reliability, Cronbach's alpha for the subscales varied between 0.81 and 0.87 and was 0.93 for the tool. Longitudinal analyses showed that changes in N-SAS scores were strongly correlated with changes in FACT-G. Multivariate analysis revealed that having a metastatic cancer diagnosis, having a low level of income, receiving taxane-based therapy and being a woman were the most important predictive factors for the well-being of the cancer patients in this study. Conclusions: The high correlation with the FACT-G suggests that the new scale is a valid instrument that can be used to evaluate the effect of antineoplastic therapies on a cancer patient's QoL and can help guide nursing care as well as track the improvement of patients' HRQoL. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:3 / 11
页数:9
相关论文
共 28 条
[1]   THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER QLQ-C30 - A QUALITY-OF-LIFE INSTRUMENT FOR USE IN INTERNATIONAL CLINICAL-TRIALS IN ONCOLOGY [J].
AARONSON, NK ;
AHMEDZAI, S ;
BERGMAN, B ;
BULLINGER, M ;
CULL, A ;
DUEZ, NJ ;
FILIBERTI, A ;
FLECHTNER, H ;
FLEISHMAN, SB ;
DEHAES, JCJM ;
KAASA, S ;
KLEE, M ;
OSOBA, D ;
RAZAVI, D ;
ROFE, PB ;
SCHRAUB, S ;
SNEEUW, K ;
SULLIVAN, M ;
TAKEDA, F .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (05) :365-376
[2]   The quality of life and self-efficacy of Turkish breast cancer patients undergoing chemotherapy [J].
Akin, Semiha ;
Can, Gulbeyaz ;
Durna, Zehra ;
Aydiner, Adnan .
EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2008, 12 (05) :449-456
[3]  
[Anonymous], 2003, TURKISH J CANC
[4]  
[Anonymous], WHO FIGHT CANC STRAT
[5]  
Arslan S, 2003, J ATATURK U SCH NURS, V6, P38
[6]  
BEKTAS HA, 2008, CANC NURSING, V31, pE7
[7]  
Beser N, 2003, J CU SCH NURS, V7, P47
[8]  
CAN G, 2008, J BALKAN UNION ON S1, V13, P75
[9]   THE FUNCTIONAL ASSESSMENT OF CANCER-THERAPY SCALE - DEVELOPMENT AND VALIDATION OF THE GENERAL MEASURE [J].
CELLA, DF ;
TULSKY, DS ;
GRAY, G ;
SARAFIAN, B ;
LINN, E ;
BONOMI, A ;
SILBERMAN, M ;
YELLEN, SB ;
WINICOUR, P ;
BRANNON, J ;
ECKBERG, K ;
LLOYD, S ;
PURL, S ;
BLENDOWSKI, C ;
GOODMAN, M ;
BARNICLE, M ;
STEWART, I ;
MCHALE, M ;
BONOMI, P ;
KAPLAN, E ;
TAYLOR, S ;
THOMAS, CR ;
HARRIS, J .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (03) :570-579
[10]   Quality of life assessment in a cross-cultural context: Use of the Rotterdam Symptom Checklist in a multinational randomised trial comparing CMF and Zoladex (Goserlin) treatment in early breast cancer [J].
de Haes, JCJM ;
Olschewski, M .
ANNALS OF ONCOLOGY, 1998, 9 (07) :745-750